Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival

[1]  Higinio Mora-Mora,et al.  μ-MAR: Multiplane 3D Marker based Registration for depth-sensing cameras , 2015, Expert Syst. Appl..

[2]  S. T. Eblen,et al.  EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK. , 2012, Translational oncology.

[3]  Caroline Kampf,et al.  Production of Tissue Microarrays, Immunohistochemistry Staining and Digitalization Within the Human Protein Atlas , 2012, Journal of visualized experiments : JoVE.

[4]  Yao-guang Jiang,et al.  BCAR1 Protein Plays Important Roles in Carcinogenesis and Predicts Poor Prognosis in Non-Small-Cell Lung Cancer , 2012, PloS one.

[5]  P. Bedossa,et al.  Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma , 2012, Pancreas.

[6]  A. Causse,et al.  Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. , 2011, Cancer research.

[7]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[8]  P. Wen,et al.  Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. , 2010, International journal of radiation oncology, biology, physics.

[9]  Yan Sun,et al.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. , 2010, The Lancet. Oncology.

[10]  R. Stupp,et al.  High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  H. Soininen,et al.  Analysis of human tau in cerebrospinal fluid. , 2010, Journal of proteome research.

[12]  H. Soininen,et al.  Brain pathology in three subjects from the same pedigree with presenilin‐1 (PSEN1) P264L mutation , 2010, Neuropathology and applied neurobiology.

[13]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[14]  T. Haas,et al.  p38 MAPK activity is stimulated by vascular endothelial growth factor receptor 2 activation and is essential for shear stress‐induced angiogenesis , 2010, Journal of cellular physiology.

[15]  I. Alafuzoff,et al.  The Effect of Prolonged Fixation Time on Immunohistochemical Staining of Common Neurodegenerative Disease Markers , 2010, Journal of neuropathology and experimental neurology.

[16]  M. J. van den Bent,et al.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Soininen,et al.  Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer’s disease , 2009, Analytical and bioanalytical chemistry.

[18]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[19]  A. Norberg,et al.  Nutritional status in patients with acute stroke. , 2009, Acta medica Scandinavica.

[20]  Lixin Wei,et al.  Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells , 2008, BMC Cancer.

[21]  Elin Lindhagen,et al.  The fluorometric microculture cytotoxicity assay , 2008, Nature Protocols.

[22]  C. Beaudry,et al.  MAP-ing glioma invasion: Mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival , 2007, Molecular Cancer Therapeutics.

[23]  T. Morimoto,et al.  Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. , 2006, International journal of oncology.

[24]  G. Fontanini,et al.  Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma , 2005, Clinical Cancer Research.

[25]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[26]  I. Alafuzoff,et al.  Glycosylation changes in Alzheimer’s disease as revealed by a proteomic approach , 2004, Neuroscience Letters.

[27]  Lajos Pusztai,et al.  Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma , 2004, Cancer.

[28]  H. Soininen,et al.  Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology , 2003, Neuroscience Letters.

[29]  M. Berger,et al.  The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents , 2003, Molecular and Cellular Biology.

[30]  H. Braak,et al.  Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. , 2003, The American journal of pathology.

[31]  S. Kliche,et al.  p38 MAPK inhibition is critically involved in VEGFR-2-mediated endothelial cell survival. , 2003, Biochemical and biophysical research communications.

[32]  H. Soininen,et al.  Reelin-immunoreactive Cajal-Retzius cells: the entorhinal cortex in normal aging and Alzheimer's disease , 2003, Acta Neuropathologica.

[33]  I. Alafuzoff,et al.  Brain biopsy prior to treatment of Alzheimer's disease. , 2003, Minimally invasive neurosurgery : MIN.

[34]  H. Soininen,et al.  Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. , 2003, Journal of neuropathology and experimental neurology.

[35]  H. Braak,et al.  Role of protein kinase B in Alzheimer's neurofibrillary pathology , 2003, Acta Neuropathologica.

[36]  P. Taipale,et al.  Prenatal diagnosis of holoprosencephaly and ectopia cordis in a twin at 12 weeks' gestation , 2003, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[37]  T. Lehtimäki,et al.  Absence of association between an intercellular adhesion molecule 1 gene E469K polymorphism and Alzheimer's disease in Finnish patients , 2003, Neuroscience Letters.

[38]  M Vapalahti,et al.  Long term outcome of temporal lobe epilepsy surgery: analyses of 140 consecutive patients , 2002, Journal of neurology, neurosurgery, and psychiatry.

[39]  I. Alafuzoff,et al.  Castleman's disease of the leptomeninges--immunohistochemical findings in 2 cases. , 2002, Clinical neuropathology.

[40]  I. Alafuzoff,et al.  Proteomic analysis of protein oxidation in Alzheimer's disease brain , 2002, Electrophoresis.

[41]  H. Soininen,et al.  Molecular genetic analysis of the α‐synuclein and the parkin gene in Parkinson's disease in Finland , 2002, European journal of neurology.

[42]  M. Laakso,et al.  Interleukin 1 Alpha Gene Polymorphism as a Susceptibility Factor in Alzheimer’s Disease and Its Influence on the Extent of Histopathological Hallmark Lesions of Alzheimer’s Disease , 2002, Dementia and Geriatric Cognitive Disorders.

[43]  H. Soininen,et al.  Seladin-1 transcription is linked to neuronal degeneration in Alzheimer’s disease , 2002, Neuroscience.

[44]  I. Alafuzoff,et al.  Five-Year Outcome of Normal Pressure Hydrocephalus with or Without a Shunt: Predictive Value of the Clinical Signs, Neuropsychological Evaluation and Infusion Test , 2002, Acta Neurochirurgica.

[45]  E. Kuusisto,et al.  Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation , 2002, Neuropathology and applied neurobiology.

[46]  W. Rom,et al.  Selective p38 activation in human non-small cell lung cancer. , 2002, American journal of respiratory cell and molecular biology.

[47]  H. Tanila,et al.  Brain prolyl oligopeptidase activity is associated with neuronal damage rather than β-amyloid accumulation , 2001, Neuroreport.

[48]  H. Soininen,et al.  α‐Synuclein pathology is highly dependent on the case selection , 2001, Neuropathology and applied neurobiology.

[49]  E. Kuusisto,et al.  Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies , 2001, Neuroreport.

[50]  M. Laakso,et al.  An association between a subset of Finnish late-onsetAlzheimer’s disease and alpha2-macroglobulin , 2001, Neurogenetics.

[51]  H. Soininen,et al.  The load and distribution of β‐amyloid in brain tissue of patients with Alzheimer's disease , 2001, Acta neurologica Scandinavica.

[52]  J. Karhu,et al.  Auditory event-related potentials differentiate patients with normal pressure hydrocephalus and patients with concomitant Alzheimer's disease verified by brain biopsy , 2001, Neuroreport.

[53]  H. Soininen,et al.  Severity of Cardiovascular Disease, Apolipoprotein E Genotype, and Brain Pathology in Aging and Dementia , 2000, Annals of the New York Academy of Sciences.

[54]  H. Soininen,et al.  Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early onset Alzheimer's disease family: an Alu core sequence-stimulated recombination? , 2000, European Journal of Human Genetics.

[55]  H. Soininen,et al.  Morphology of spiny neurons in the human entorhinal cortex: intracellular filling with Lucifer Yellow , 2000, Neuroscience.

[56]  H. Soininen,et al.  MR imaging of the hippocampus in normal pressure hydrocephalus: correlations with cortical Alzheimer's disease confirmed by pathologic analysis. , 2000, AJNR. American journal of neuroradiology.

[57]  H. Soininen,et al.  Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease , 2000, European Journal of Clinical Pharmacology.

[58]  H. Soininen,et al.  Is the presenilin-1 E318G missense mutation a risk factor for Alzheimer's disease? , 2000, Neuroscience Letters.

[59]  I. Alafuzoff,et al.  Upregulated expression of Fas and Fas ligand in brain through the spectrum of HIV-1 infection , 1999, Acta Neuropathologica.

[60]  I. Alafuzoff,et al.  A case of sudden death caused by fibromuscular dysplasia. , 1999, Journal of clinical pathology.

[61]  H. Soininen,et al.  Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28k immunoreactivity in the entorhinal cortex in Alzheimer's disease , 1999, Neuroscience.

[62]  H. Soininen,et al.  Rapidly progressive multifocal leukoencephalopathy with substantial cell-mediated inflammatory response and with cognitive decline of non-Alzheimer type in a 75-year-old female patient. , 1999, Clinical neuropathology.

[63]  Hilkka Soininen,et al.  Hippocampal plasticity in Alzheimer's disease: changes in highly polysialylated NCAM immunoreactivity in the hippocampal formation , 1999, The European journal of neuroscience.

[64]  M. Laakso,et al.  Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue , 1999, Acta Neuropathologica.

[65]  H. Soininen,et al.  Pitfalls in the quantitative estimation of β-amyloid immunoreactivity in human brain tissue , 1998, Histochemistry and Cell Biology.

[66]  H. Soininen,et al.  Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer's disease , 1998, The Lancet.

[67]  H. Soininen,et al.  The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease , 1997, Neuroreport.

[68]  B. Winblad,et al.  Intact brain serotonin system in vascular dementia. , 1996, Dementia.

[69]  I. Alafuzoff,et al.  The selection for post-mortem examination: a retrospective analysis of 74 deceased surgical cases. , 1993, Quality assurance in health care : the official journal of the International Society for Quality Assurance in Health Care.

[70]  B. Winblad,et al.  Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy , 1993, Behavioural Brain Research.

[71]  A. Nordberg,et al.  Coupling of muscarinic receptors to GTP proteins in postmortem human brain — alterations in Alzheimer's disease , 1993, Neuroscience Letters.

[72]  A. Nordberg,et al.  Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists , 1992, Brain Research.

[73]  K. Kristensson,et al.  Lipid Composition in Different Regions of the Brain in Alzheimer's Disease/Senile Dementia of Alzheimer's Type , 1992, Journal of neurochemistry.

[74]  I. Alafuzoff.  The pathology of dementias: an overview , 1992, Acta neurologica Scandinavica. Supplementum.

[75]  B. Winblad,et al.  Adenylyl Cyclase Activity in Postmortem Human Brain: Evidence of Altered G Protein Mediation in Alzheimer's Disease , 1992, Journal of neurochemistry.

[76]  B. Winblad,et al.  Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia , 1992, Journal of neuroscience research.

[77]  B. Winblad,et al.  Characterization and quantification of 125I-bolton hunter substance P binding sites in human brain , 1991, Neurochemistry International.

[78]  B. Winblad,et al.  Characterization and regional distribution of adenylyl cyclase activity from human brain , 1991, Neurochemistry International.

[79]  B. Winblad,et al.  Preservation of 5-hydroxytryptamine1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease , 1991, Neuroscience Letters.

[80]  B. Winblad,et al.  Coupling of human brain cerebral cortical α 2-adrenoceptors to GTP-binding proteins in Alzheimer's disease , 1991, Brain Research.

[81]  P. Greengard,et al.  Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[82]  B. Winblad,et al.  Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain , 1991, Journal of the Neurological Sciences.

[83]  B. Winblad,et al.  Somatostatin receptors and the modulation of adenylyl cyclase activity in Alzheimer's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[84]  I. Alafuzoff,et al.  Granulomatous peritonitis and appendicitis of food starch origin. , 1991, Gut.

[85]  I. Alafuzoff,et al.  [High frequency of autopsies at regional centers is desirable]. , 1991, Lakartidningen.

[86]  B. Winblad,et al.  Assay of a phosphatidylinositol bisphosphate phospholipase C activity in postmortem human brain , 1991, Brain Research.

[87]  K. Blomgren,et al.  Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue , 1990, Neurobiology of Aging.

[88]  B. Winblad,et al.  Neurotransmitter deficits in a non‐multi‐infarct category of vascular dementia , 1989, Acta neurologica Scandinavica.

[89]  B. Winblad,et al.  5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders , 1987, Brain Research.

[90]  B. Winblad,et al.  DEFECTIVE BRAIN MICROTUBULE ASSEMBLY IN ALZHEIMER'S DISEASE , 1986, The Lancet.

[91]  C. Gottfries.  Transmitter deficits in Alzheimer's disease , 1985, Neurochemistry International.

[92]  Gösta Bucht,et al.  Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of alzheimer type and multi-infarct dementia , 1983, Journal of the Neurological Sciences.

[93]  Elin Lindhagen,et al.  The Fluorometric Microculture Cytotoxicity Assay. Nat Protoc 3:1364 , 2008 .

[94]  B. Winblad,et al.  Muscarinic receptor compensation in hippocampus of Alzheimer patients , 2005, Journal of Neural Transmission.

[95]  B. Winblad,et al.  Neurotransmitter-mediated inhibition of post-mortem human brain adenylyl cyclase , 2005, Journal of Neural Transmission / General Section JNT.

[96]  K. Blennow,et al.  Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele , 2005, Journal of Neural Transmission.

[97]  P. Greengard,et al.  Synapsin I (protein I) in different brain regions in senile dementia of Alzheimer type and in multiinfarct dementia , 2005, Journal of Neural Transmission.

[98]  B. Winblad,et al.  Perivascular deposits of serum proteins in cerebral cortex in vascular dementia , 2004, Acta Neuropathologica.

[99]  B. Winblad,et al.  Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis , 2004, Acta Neuropathologica.

[100]  A. Ylinen,et al.  Preoperative clinical evaluation, outline of surgical technique and outcome in temporal lobe epilepsy. , 2004, Advances and technical standards in neurosurgery.

[101]  A. Ylinen,et al.  Neurobiology of epileptogenesis in the temporal lobe. , 2002, Advances and technical standards in neurosurgery.

[102]  Jiahuai Han,et al.  The p38 signal transduction pathway: activation and function. , 2000, Cellular signalling.

[103]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. , 2000, Neuroscience letters.

[104]  H. Soininen,et al.  MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. , 2000, Neurology.

[105]  H. Soininen,et al.  Lower Counts of Astroglia and Activated Microglia in Patients with Alzheimer's Disease with Regular Use of Non-Steroidal Anti-Inflammatory Drugs. , 2000, Journal of Alzheimer's disease : JAD.

[106]  M. Laakso,et al.  Astrogliosis and the ApoE genotype. an immunohistochemical study of postmortem human brain tissue. , 1999, Dementia and geriatric cognitive disorders.

[107]  B. Winblad,et al.  A comparison of multiplex and simplex families with Alzheimer's disease/senile dementia of Alzheimer type within a well defined population , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[108]  B. Winblad,et al.  How to run a brain bank: potentials and pitfalls in the use of human post-mortem brain material in research. , 1993, Journal of neural transmission. Supplementum.

[109]  I. Alafuzoff,et al.  Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[110]  A. Herlitz,et al.  Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[111]  I. Alafuzoff,et al.  Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease. , 1990, European neurology.

[112]  B. Winblad,et al.  New approaches to clinical and postmortem investigations of cholinergic mechanisms. , 1990, Progress in brain research.

[113]  B. Winblad,et al.  The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. , 1989, Progress in brain research.

[114]  B. Winblad,et al.  Histopathological classification of dementias by multivariate data analysis. , 1989, Progress in clinical and biological research.

[115]  B. Winblad,et al.  Isoelectric focusing and two-dimensional gel electrophoresis in plasma and cerebrospinal fluid from patients with dementia. , 1986, European neurology.

[116]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[117]  B. Winblad,et al.  Blood components in an elderly population. , 1984, Gerontology.